Facilitating European Clinical Research

ECRIN is a public, non-profit organisation that links scientific partners and networks across Europe
to facilitate multinational clinical research. We provide sponsors and investigators with advice,
management services and tools to overcome hurdles to multinational trials and enhance collaboration.

Our Work

We provide our 12 member and observer countries with diverse trial support services
and contribute to 'infrastructure development' projects with additional European and international partners.

ECRIN in Numbers

Member & Observer Countries

Million citizens represented

Trials in ECRIN portfolio

Average # of countries per trial



In this EOSC-Life workshop “Sharing sensitive data – centralised, federated or hybrid?”, we will examine the pros and cons of data sharing approaches by taking a look at specific use cases in the life sciences domain. 

Large-scale research collaborations in life sciences face a wide range of challenges when jointly gathering sensitive data to address research questions. First of all, ethical and legal issues need to be addressed, but there is also a wide range of other aspects to be considered: data ownership, technical requirements and system performance, data privacy and security, data quality and sustainability.

The workshop goal is to offer clear guidance: When should research collaborations centralise the data collections and when is it better to opt for a federated or hybrid approach? What would be the key organizational and technical measures to take in either case?

Register for the event and join us on the 27th September!

Draft agenda is available here. For more background information on the scope of the workshop click here.


While great progress has been made in recent years in the development of public health within the European Union (EU), the Covid-19 pandemic brought to light existing vulnerabilities in the European health response mechanism, from Member State incoordination to difficulties in manufacturing and accessing medicines, to EU research fragmentation and differences between corporate R&D choices and public health priorities.

On 2 June 2020, the European Commission published its roadmap for a pharmaceutical strategy for Europe, fostering access to affordable high-quality, effective and safe medicines and supporting innovation in the EU pharmaceutical industry. With its resolution of 17 September 2020 on shortages of medicines, the European Parliament called on the Commission and Member States to 'examine the possibility of creating one or more European non-profit pharmaceutical undertakings which operate in the public interest to manufacture medicinal products'. The December 2021 Council conclusions suggested examining Parliament's resolution to ensure the supply of medicinal products affected by market failures.

With these objectives in mind, a recent STOA study investigated the feasibility of creating a large-scale European public infrastructure aimed at addressing vulnerabilities linked to the research, development, production and distribution of medicines. This workshop will bring together experts from biomedical research, representatives of the pharmaceutical industry, and EU and international public health experts to discuss the state-of-play of the EU's current pharmaceutical strategy and explore policy options for strengthening EU preparedness and response, including the feasibility of creating an advanced EU pharmaceutical infrastructure for the research and development of novel medicines and treatments.

For more information and registration visit the dedicated website


For the first time in two years, ICPerMed is delighted to organise a physical meeting and to welcome you in Paris on October 5-6, 2022 for the ICPerMed Conference – Prelude to the Future of Medicine.
The conference will provide an insight into what the future of medicine will look like by presenting concrete examples of personalised medicine approaches and aspects already being in practice. From rare diseases, cancer, chronic inflammatory diseases, cardiovascular diseases to neurodegenerative diseases, the conference will demonstrate that implementation of personalised medicine is progressing through all disciplines and medical fields and aims to inspire other initiatives to adopt similar approaches.

Come and learn about:

• Incorporating patient’s perspective in personalised healthcare
• The future of personalised medicine in clinical setting
• Challenges in developing health data governance
• Health economic benefits – beyond cost-effectiveness
• Creating a sustainable innovation environment for personalised medicine
•      ...


Experts will be invited to present their activities and projects and will discuss further about opportunities and hurdles of translating personalised medicine into practice to decipher the requirements for implementation to overcome for a general adoption in healthcare.


ICPerMed will feature and honour during the conference best practices in personalised medicine research with the ICPerMed Recognition 2022, aiming to recognise, encourage, promote and disseminate outstanding examples. A specific session will be dedicated to present these best practices during the conference in form of short talks accompanied by posters.
A Stakeholder Forum session will offer a platform to 4 selected members of the Stakeholder Forum to present their activities.


For more information and registration visit the dedicated website